fampridine

Fampyra · ATC code N07XX07

Also known as: Fampridin · Brand names: Fampyra, Fampridin Neuraxpharm, Fampridin Ratiopharm, Fampridin Stada, Fampridin Abdi, Fampridin Abz, Fampridin Al, Fampridin Ascend, Fampridin Axiromed, Fampridin Basics, Fampridin Beta, Fampridin Heumann, Fampridin Hexal, Fampridin Liconsa, Fampridin Micro Labs …

Key facts
Active substance: fampridine
ATC code: N07XX07
Authorisation: centrally authorised across the EU (EMA)
Dosage forms: Fampyra 10 mg prolonged-release tablets
Marketing authorisation holder: Merz Therapeutics GmbH
Information as of: 2026-10-27

Key facts

Fampridine is a potassium channel blocker used to improve walking in adults with multiple sclerosis who have walking disability (EDSS 4-7).

What it is used for

Improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7)

Dosing

One 10 mg prolonged-release tablet twice daily, 12 hours apart, without food; not more often or at higher doses
Initial prescription limited to two to four weeks; assess walking ability and stop if there is no improvement
If walking ability declines, consider an interruption to reassess benefit
Moderate and severe renal impairment (creatinine clearance below 50 mL/min): contraindicated; check renal function in the elderly before starting
No adjustment in hepatic impairment; swallow the tablet whole

Contraindications

Hypersensitivity to fampridine or any excipient
Concurrent treatment with other fampridine (4-aminopyridine) products
Prior history or current presentation of seizure
Moderate or severe renal impairment
Concomitant OCT2 inhibitors (e.g. cimetidine)

Important warnings

Increased seizure risk; discontinue if a seizure occurs
Renally excreted: check renal function before and regularly during treatment
Serious hypersensitivity reactions including anaphylaxis, mostly in the first week; discontinue and do not restart
Caution with mild renal impairment and OCT2 substrates

Side effects

Most frequent: urinary tract infection (approximately 12%)
Mostly neurological: seizure, insomnia, anxiety, balance disorder, dizziness, paraesthesia, tremor, headache, asthenia
Uncommon: anaphylaxis, angioedema, hypersensitivity

Interactions

OCT2 inhibitors (e.g. cimetidine): contraindicated
OCT2 substrates (e.g. carvedilol, propranolol, metformin): caution
No pharmacokinetic interactions observed with interferon-beta or baclofen

Pregnancy and breastfeeding

As a precaution, use in pregnancy is preferably avoided
Not recommended during breast-feeding

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Fampridine Accord · genericAccord Healthcare S.L.U. · EMEA/H/C/005359
FampyraMerz Therapeutics GmbH · EMEA/H/C/002097

Source: European Medicines Agency (EMA), product information

Austria

Fampridin NeuraxpharmNeuraxpharm Arzneimittel Gmbh · 1 register entry
Fampridin RatiopharmRatiopharm Arzneimittel Vertriebs-Gmbh · 1 register entry
Fampridin StadaStada Arzneimittel Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Germany

Fampridin AbdiAbdi Farma Gmbh · 1 register entry
Fampridin AbzRatiopharm Gmbh · 1 register entry
Fampridin AlAliud Pharma Gmbh · 1 register entry
Fampridin AscendAscend Gmbh · 1 register entry
Fampridin AxiromedMedical Valley Invest Ab · 1 register entry
Fampridin BasicsBasics Gmbh · 1 register entry
Fampridin BetaBetapharm Arzneimittel Gmbh · 1 register entry
Fampridin HeumannHeumann Pharma Gmbh & Co. Generica Kg · 1 register entry
Fampridin HexalHexal Ag · 1 register entry
Fampridin LiconsaLaboratorios Liconsa S.A. · 1 register entry
Fampridin Micro LabsMicro Labs Gmbh · 1 register entry
Fampridin NeuraxpharmNeuraxpharm Arzneimittel Gmbh · 1 register entry

Show all 19 brand names

Fampridin PurenPuren Pharma Gmbh & Co. Kg · 1 register entry
Fampridin RatiopharmRatiopharm Gmbh · 1 register entry
Fampridin RontisRontis Hellas Sa · 1 register entry
Fampridin StadaStadapharm Gmbh · 1 register entry
Fampridin ViatrisViatris Germany Gmbh · 1 register entry
Fampridin ZentivaZentiva Pharma Gmbh · 1 register entry
PrijidinVale Pharmaceuticals Limited · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Turkey

ArtimeALİ RAİF İLAÇ SAN. A.Ş. · 2 register entries
FampraxaBİOFARMA İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
FamprimesTEVA İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
FarnapinFARMA-TEK İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
HalfprinABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 22 more European countries

Croatia: Fampridin Sandoz, Fampridin Teva
Cyprus: Fampridine Sandoz, Fampridine Viatris
Czechia: Fampridin Sandoz, Fampridine Abdi, Fampridine Teva
Denmark: Fampridin "neuraxpharm", Fampridin Medical Valley, Fampridin Teva, Fampridin Zentiva, Fampridine Newbury, Fampridine Sandoz, Fampridine Stada, Fampridine Viatris
Finland: Fampridin Medical Valley, Fampridin Zentiva, Fampridine Laboratorios Liconsa, Fampridine Sandoz, Fampridine Stada
France: Fampridine Arrow, Fampridine Eg, Fampridine Lp Biogaran, Fampridine Lp Sandoz, Fampridine Lp Teva, Fampridine Lp Zentiva, Fampridine Rontis Lp, Fampridine Teva, Fampridine Viatris
Greece: Fadisa, Fampridine Sandoz, Fampridine Stada, Fampridine Viatris, Pristep
Hungary: Fampridine Rontis
Iceland: Fampridin Medical Valley, Fampridin Neuraxpharm, Fampridine Accord, Fampridine Stada, Fampridine Viatris, Fampyra
Ireland: Fampridine Rowa
Italy: Fampridina Abdi
Liechtenstein: Fampridine Accord, Fampyra
Luxembourg: Fampridine Eg
Malta: Fampridine Viatris
Netherlands: Fampridine Abdi, Fampridine Ascend, Fampridine Aurobindo, Fampridine Cf, Fampridine Neuraxpharm, Fampridine Sandoz, Fampridine Sun, Fampridine Teva, Fampridine Viatris, Fampridine Xiromed, Pristep
Norway: Fampridin Medical Valley, Fampridin Neuraxpharm, Fampridin Teva, Fampridin Zentiva, Fampridine Accord, Fampridine Newbury, Fampridine Sandoz, Fampridine Stada, Fampridine Viatris, Fampyra
Poland: Fampridine Sandoz, Fampridine Teva, Fampridine Zentiva
Portugal: Fampridina Ascend, Fampridina Generis, Fampridina Mylan, Fampridina Teva, Fampridine Mylan
Slovakia: Fampridine Sandoz, Fampridín Teva
Slovenia: Fampridin Stada, Fampridin Teva
Spain: Fampridina Aurovitas, Fampridina Qualigen, Fampridina Stada
Sweden: Fampridin Medical Valley, Fampridin Zentiva, Fampridine Neuraxpharm, Fampridine Newbury, Fampridine Sandoz, Fampridine Stada

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

European Medicines Agency. Fampyra – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/fampyra-epar-product-information_en.pdf
EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.